By Fineline Cube Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced successful unblinding of two pivotal Phase III clinical trials for LH-1801, its Class 1 novel SGLT-2 inhibitor co-developed with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The drug demonstrated non-inferiority to dapagliflozin in combination therapy and superiority over placebo as monotherapy for type 2 diabetes (T2D) in Chinese adult patients.
Clinical Trial Overview
| Trial Design | Patient Population | Primary Endpoint | Key Result |
|---|---|---|---|
| Combination Therapy | T2D adults on metformin with inadequate glycemic control | HbA1c reduction vs. dapagliflozin + metformin | Non-inferior to active comparator |
| Monotherapy | T2D adults controlled by diet/exercise alone | HbA1c reduction vs. placebo | Statistically superior to placebo |
Drug Profile & Development Partnership
- Molecule: LH-1801, novel SGLT-2 inhibitor (Class 1 innovative drug)
- Target Indication: Type 2 diabetes mellitus (T2D)
- Development Partnership: Co-developed with Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Regulatory Status: Class 1 designation indicates first-in-class or best-in-class potential under China’s NMPA classification
- Commercial Rights: Jiangsu Lianhuan holds exclusive marketing rights in Greater China; global partnership discussions ongoing
Clinical Evidence Summary
Combination Therapy Trial
The Phase III study evaluating LH-1801 plus metformin versus dapagliflozin plus metformin met its primary endpoint of non-inferiority in glycemic efficacy. Secondary endpoints included safety profile, weight reduction, and blood pressure effects, with full data expected in Q3 2026.
Monotherapy Trial
The monotherapy study demonstrated that LH-1801 as a single agent achieved statistically significant and clinically meaningful reductions in HbA1c compared to placebo in patients whose diabetes was inadequately controlled by lifestyle modifications alone.
Market Context & Competitive Landscape
- SGLT-2 Inhibitor Market: Global market valued at $9.8 billion in 2025, projected to reach $14.2 billion by 2030
- China T2D Prevalence: Over 140 million adults with diabetes, representing the world’s largest diabetic population
- Competitive Positioning: LH-1801 would be the fifth SGLT-2 inhibitor approved in China if successful, joining dapagliflozin, empagliflozin, canagliflozin, and ertugliflozin
- Differentiation Strategy: Potential advantages in safety profile, dosing convenience, or cost-effectiveness to be detailed in complete data disclosure
Regulatory and Commercial Outlook
- NMPA Submission Timeline: Marketing application expected in Q4 2026 following completion of full data analysis
- Revenue Projections: Analysts estimate peak annual sales of ¥800 million–¥1.2 billion ($110–170 million) assuming 3–5% market share capture
- Reimbursement Strategy: Target inclusion in National Reimbursement Drug List (NRDL) negotiations scheduled for 2027
- Manufacturing Capacity: Existing production facilities capable of meeting initial demand; expansion plans contingent on approval timeline
Investment Implications
- Stock Performance: SHA: 600513 closed at ¥28.45 on May 7, 2026; trading volume expected to increase following announcement
- Pipeline Valuation: LH-1801 represents the company’s most advanced asset; successful approval could double enterprise value
- Partnership Opportunities: International pharma companies monitoring development progress for potential licensing agreements
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical trial results, regulatory submissions, and commercial projections for LH-1801. Actual outcomes may differ due to regulatory review timelines, competitive dynamics, and market adoption rates.-Fineline Info & Tech